Bank of The West Sells 705 Shares of Celgene Corporation (CELG)

Bank of The West trimmed its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 10.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,233 shares of the biopharmaceutical company’s stock after selling 705 shares during the period. Bank of The West’s holdings in Celgene Corporation were worth $809,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of CELG. Investec Asset Management LTD acquired a new position in shares of Celgene Corporation during the 1st quarter worth about $194,490,000. Clearbridge Investments LLC boosted its stake in shares of Celgene Corporation by 24.1% during the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock worth $572,617,000 after buying an additional 892,392 shares during the last quarter. State Street Corp boosted its stake in shares of Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares during the last quarter. Pioneer Investment Management Inc. boosted its stake in shares of Celgene Corporation by 15.7% during the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares during the last quarter. Finally, Swiss National Bank boosted its stake in shares of Celgene Corporation by 27.2% during the 1st quarter. Swiss National Bank now owns 2,746,896 shares of the biopharmaceutical company’s stock worth $341,796,000 after buying an additional 588,000 shares during the last quarter. Institutional investors own 79.33% of the company’s stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.08% on Friday, reaching $143.89. 3,549,466 shares of the company were exchanged. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $144.19. The firm has a 50 day moving average price of $135.45 and a 200-day moving average price of $127.81. The stock has a market capitalization of $112.57 billion, a PE ratio of 44.56 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. Celgene Corporation’s revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.44 EPS. On average, analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

In related news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the sale, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the sale, the director now directly owns 69,424 shares in the company, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold a total of 63,006 shares of company stock worth $8,490,806 in the last ninety days. 0.95% of the stock is currently owned by insiders.

WARNING: This piece of content was first posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.truebluetribune.com/2017/09/23/bank-of-the-west-sells-705-shares-of-celgene-corporation-celg.html.

A number of equities analysts have recently commented on the stock. Robert W. Baird restated a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a research note on Thursday. Bank of America Corporation restated a “buy” rating on shares of Celgene Corporation in a research note on Wednesday, September 13th. Jefferies Group LLC restated a “buy” rating and set a $160.00 price objective on shares of Celgene Corporation in a research note on Friday, September 15th. Cowen and Company restated a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a research note on Tuesday, September 12th. Finally, Royal Bank Of Canada assumed coverage on shares of Celgene Corporation in a research note on Thursday, September 14th. They set a “top pick” rating and a $176.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $149.34.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply